Leuprolide injection

Patent metadata

Field	Value
Publication number	US-9656023-B2
Application number	US-201414172384-A
Country	US
Kind code	B2
Filing date	Feb 4, 2014
Priority date	Apr 30, 2012
Publication date	May 23, 2017
Grant date	May 23, 2017

Abstract

The present invention provides a sterile solution comprising leuprolide acetate in a pharmaceutically acceptable vehicle, wherein solution is present as a reservoir in a multiple dose pen injection device, the device being adapted to subcutaneously inject a portion of the said reservoir in a single daily dose and further being adapted to provide multiple portions of solution said while the reservoir remains sterile.

First claim

We claim:

1. A multiple dose leuprolide acetate pen injection device containing a sterile solution comprising leuprolide acetate in an amount of 10 mg per ml of the solution and at least one preservative in a pharmaceutically acceptable vehicle in an amount sufficient to maintain sterility of the solution throughout the shelf life of the sterile solution, wherein the solution is present as a reservoir in the multiple dose pen injection device, the device being adapted to subcutaneously inject a portion of the reservoir to provide a single daily dose of leuprolide and the device further being adapted to inject multiple portions of the solution while the reservoir remains sterile,
wherein the multiple dose pen injection device is configured to administer 100 microliters of the solution to provide the single daily dose of leuprolide, and
wherein the preservative is benzyl alcohol and is present in a concentration of 11.25 mg per ml of the solution.

2. The multiple dose leuprolide acetate pen injection device as claimed in claim 1 wherein the reservoir contains 28 doses of said sterile solution of leuprolide acetate.

3. The multiple dose leuprolide acetate pen injection device as claimed in claim 1 further comprising a dose dialing facility having a dose dial with a range of markings visible through a dose window.

4. The multiple dose leuprolide acetate pen injection device as claimed in claim 3 further comprising a dose set knob to select a desired dose.

5. The multiple dose leuprolide acetate pen injection device as claimed in claim 4 wherein the dose dial has markings to indicate a volume of the sterile solution to be administered.

6. The multiple dose leuprolide acetate pen injection device as claimed in claim 4 wherein the dose dial has markings to indicate an amount of the leuprolide acetate to be administered.

7. A multiple dose leuprolide acetate pen injection device containing a sterile solution comprising leuprolide acetate in an amount of 10 mg per ml of the solution and at least one preservative in a pharmaceutically acceptable vehicle in an amount sufficient to maintain sterility of the solution throughout the shelf life of the sterile solution, wherein the solution is present as a reservoir in the multiple dose pen injection device, the device being adapted to subcutaneously inject a portion of the reservoir to a single daily dose of leuprolide and the device further being adapted to inject multiple portions of the solution while the reservoir remains sterile,
wherein the multiple dose pen injection device is configured to administer 100 microliters of the solution to provide the single daily dose of leuprolide and
wherein the solution remains stable when kept at 40° C./75% RH for 3 months.

8. The multiple dose leuprolide acetate pen injection device as claimed in claim 7 wherein the reservoir contains 28 doses of said sterile solution of leuprolide acetate.

9. The multiple dose leuprolide acetate pen injection device as claimed in claim 7 further comprising a dose dialing facility having a dose dial with a range of markings visible through a dose window.

Assignees

• Sun Pharmaceuticals Ltd
• Sun Pharmaceutical Ind Ltd

Inventors

• George Alex
• Kane Prashant
• Bhowmick Subhas

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P5/10

  of the posterior pituitary hormones, e.g. oxytocin, ADH · CPC title

• A61P5/02

  of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin · CPC title

• A61P13/08

  of the prostate · CPC title

• A61M5/3155

  by rotational movement of dose setting member, e.g. during setting or filling of a syringe · CPC title